Public ID: PID-9ZOKXB
Lack of comprehensive cost-benefit evaluation for medical products in Panama disadvantages UK exporters
Trade barrier summary
Government purchases of medicines and medical products does not follow a comprehensive cost-benefit evaluation of the product. This makes it difficult for UK companies looking to introduce new and innovative technologies and treatments in the market.
- Healthcare services
- Pharmaceuticals and biotechnology
23 April 2021
26 November 2021